Skip to main content
Journal cover image

Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.

Publication ,  Journal Article
Zimerman, A; Lopes, RD; Stebbins, AL; Guimarães, PO; Haque, G; Melloni, C; Trollinger, K; James, SK; Alexander, JH; Tricoci, P; Roe, MT ...
Published in: Am Heart J
April 2016

BACKGROUND: Adverse event collection in randomized clinical trials establishes drug safety. Although costly and regulated, it is rarely studied. METHODS: Adverse event data from 4 clinical trials (APPRAISE-2, PLATO, TRACER, TRILOGY ACS) comprising 48,118 participants with acute coronary syndromes were pooled to compare patterns and determinants of reporting. Events were classified as serious (SAE) or nonserious (AE) from hospital discharge to 1 year; study end points were excluded. RESULTS: In total, 84,901 events were reported. Of those, 12,266 (14.4%) were SAEs and 72,635 (85.6%) were AEs. Of all participants, 7,823 (16.3%) had SAEs, 18,124 (37.7%) had only AEs, and 22,171 (46.1%) had neither. Nonserious adverse events were distributed across system organ classes: general disorders (11%), infection (10%), gastrointestinal (10%), respiratory (9%), cardiovascular (8.4%), and other (35%). Serious adverse events had a higher proportion of cardiovascular causes (14.0%). Event reporting was highest after hospital discharge, decreasing rapidly during the following 3 months. In a Cox proportional hazards model, chronic obstructive pulmonary disease (hazard ratio 1.58, 95% CI 1.44-1.74), heart failure (1.55, 1.40-1.70), older age, and female sex were independent predictors of more SAEs, whereas enrollment in Eastern Europe (0.63, 0.58-0.69) or Asia (0.84, 0.75-0.94) were independent predictors of fewer SAEs. CONCLUSIONS: Half of all participants reported adverse events in the year after acute coronary syndrome; most were AEs and occurred within 3 months. The high volume of events, as well as the variation in SAE reporting by characteristics and enrollment region, indicates that efforts to refine event collection in large trials are warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

April 2016

Volume

174

Start / End Page

60 / 67

Location

United States

Related Subject Headings

  • United States
  • Survival Rate
  • Risk Assessment
  • Retrospective Studies
  • Prognosis
  • Platelet Aggregation Inhibitors
  • Patient Discharge
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zimerman, A., Lopes, R. D., Stebbins, A. L., Guimarães, P. O., Haque, G., Melloni, C., … Alexander, K. P. (2016). Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. Am Heart J, 174, 60–67. https://doi.org/10.1016/j.ahj.2016.01.003
Zimerman, André, Renato D. Lopes, Amanda L. Stebbins, Patrícia O. Guimarães, Ghazala Haque, Chiara Melloni, Kathleen Trollinger, et al. “Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.Am Heart J 174 (April 2016): 60–67. https://doi.org/10.1016/j.ahj.2016.01.003.
Zimerman A, Lopes RD, Stebbins AL, Guimarães PO, Haque G, Melloni C, et al. Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. Am Heart J. 2016 Apr;174:60–7.
Zimerman, André, et al. “Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.Am Heart J, vol. 174, Apr. 2016, pp. 60–67. Pubmed, doi:10.1016/j.ahj.2016.01.003.
Zimerman A, Lopes RD, Stebbins AL, Guimarães PO, Haque G, Melloni C, Trollinger K, James SK, Alexander JH, Tricoci P, Roe MT, Ohman EM, Mahaffey KW, Held C, Tinga B, Pieper KS, Alexander KP. Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. Am Heart J. 2016 Apr;174:60–67.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

April 2016

Volume

174

Start / End Page

60 / 67

Location

United States

Related Subject Headings

  • United States
  • Survival Rate
  • Risk Assessment
  • Retrospective Studies
  • Prognosis
  • Platelet Aggregation Inhibitors
  • Patient Discharge
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged